A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Peginterferon Alfa 2a (Pegasys) And Ribavirin (Copegus) With And Without PF-00868554 In Subjects Chronically Infected With Hepatitis C Virus.

Trial Profile

A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Peginterferon Alfa 2a (Pegasys) And Ribavirin (Copegus) With And Without PF-00868554 In Subjects Chronically Infected With Hepatitis C Virus.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2013

At a glance

  • Drugs Filibuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
    • 15 Apr 2010 Results were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 09 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top